Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Guy Jerusalem,Yeon Hee Park,Toshinari Yamashita,Sara A. Hurvitz,Shanu Modi,Fabrice Andre,Ian E. Krop,Xavier Gonzalez,Peter Hall,Benoit You,Cristina Saura,Sung-Bae Kim,Cynthia Osborne,Yasuaki Sagara,Eriko Tokunaga,Yali Liu,Jillian Cathcart,Caleb Lee,Christophe Perrin

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

2021

Guy Jerusalem
Yeon Hee Park
Toshinari Yamashita
Sara A. Hurvitz
Shanu Modi
Fabrice Andre
Ian E. Krop
Xavier Gonzalez
Peter Hall
Benoit You
Cristina Saura
Sung-Bae Kim
Cynthia Osborne
Yasuaki Sagara
Eriko Tokunaga
Yali Liu
Jillian Cathcart
Caleb Lee
Christophe Perrin

526Background: Patients (pts) with HER2+ metastatic breast cancer (mBC) are at high risk of developing brain metastases (BMs), and treatment options are limited once BMs occur. T-DXd is an antibody...

Keywords:

Medicine
Internal medicine
treatment options
Oncology
Trastuzumab
in patient
Metastatic breast cancer
Subgroup analysis
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations